NASDAQ:OMIC • US82933R3084
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SINGULAR GENOMICS SYSTEMS IN (OMIC).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-07-09 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-05-15 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-03-20 | UBS | Maintains | Neutral -> Neutral |
| 2024-01-23 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-01-22 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-08-10 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2022-11-08 | Goldman Sachs | Maintains | Neutral |
| 2022-08-17 | UBS | Downgrade | Buy -> Neutral |
| 2022-08-10 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-08-10 | B of A Securities | Downgrade | Buy -> Underperform |
| 2022-07-14 | Goldman Sachs | Maintains | Buy |
| 2022-05-11 | Goldman Sachs | Maintains | Buy |
| 2022-04-13 | Goldman Sachs | Maintains | Buy |
| 2022-01-07 | B of A Securities | Upgrade | Neutral -> Buy |
| 2021-06-21 | Cowen & Co. | Initiate | Outperform |
| 2021-06-21 | JP Morgan | Initiate | Overweight |
| 2021-06-21 | Goldman Sachs | Initiate | Buy |
| 2021-06-21 | B of A Securities | Initiate | Neutral |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 770K | 2.911M 278.05% | 2.935M 0.82% | 10.35M 252.64% | 24.262M 134.42% | ||
| EBITDA YoY % growth | -60.15M -123.69% | -91.06M -51.39% | -97.391M -6.95% | -90.244M 7.34% | -90.353M -0.12% | -89.267M 1.20% | |
| EBIT YoY % growth | -61.28M -122.59% | -93.49M -52.56% | -100.901M -7.93% | -93.304M 7.53% | -93.413M -0.12% | -92.327M 1.16% | |
| Operating Margin | N/A | -12,141.56% | -3,466.20% | -3,179.01% | -902.54% | -380.54% | |
| EPS YoY % growth | N/A | -38.10 29.66% | -39.30 -3.15% | -34.66 11.81% | -32.25 6.96% | -26.95 16.43% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -8.13 15.27% | -8.62 15.50% | -8.78 -2.48% | -8.70 -29.47% | -0.31 96.24% | -0.21 97.51% | -0.23 97.33% | -0.26 97.07% | -0.28 10.00% |
| Revenue Q2Q % growth | 1.208M 11.75% | 1.855M 319.68% | 3.168M 329.85% | 4.724M 1,063.55% | 9.884M 718.21% | 13.148M 608.79% | 14.678M 363.32% | 16.208M 243.10% | 17.738M 79.46% |
| EBITDA Q2Q % growth | -20.4M 6.30% | -15.035M 41.79% | -15.065M 27.28% | -15.555M -4.26% | -15.677M 23.15% | -9.578M 36.30% | -11.036M 26.74% | -12.485M 19.74% | -13.943M 11.06% |
| EBIT Q2Q % growth | -22.555M 10.78% | -22.522M 16.11% | -22.987M -0.80% | -22.854M -26.47% | -18.595M 17.56% | -12.495M 44.52% | -13.954M 39.30% | -15.402M 32.61% | -16.861M 9.33% |
All data in USD
8 analysts have analysed OMIC and the average price target is 12.7 USD. This implies a price decrease of -36.54% is expected in the next year compared to the current price of 20.01.
SINGULAR GENOMICS SYSTEMS IN (OMIC) will report earnings on 2025-03-17, after the market close.
The consensus EPS estimate for the next earnings of SINGULAR GENOMICS SYSTEMS IN (OMIC) is -8.13 USD and the consensus revenue estimate is 1.21M USD.
The expected long term growth rate for SINGULAR GENOMICS SYSTEMS IN (OMIC) is 108.68%.